Sensible Medical raised $20 million in its latest financing round, with investment led by Boston Scientific (NYSE:BSX).
Lowell, Mass.-based Boston Scientific is also working on launch for Sensible Medical’s flagship product, a non-invasive thoracic fluid status monitor. The companies are working on getting the monitor certified in the U.S., Europe, and Japan, according to a press release.
Sensible’s round also included the likes of Shanghai LongTec Medical Technology Co., Ltd., SCP Vitalife Partners, and Genesis Partners. The Israeli company plans to use the funds to obtain additional clinical data and commercialize the product globally.
Boston Scientific closed its $275 million acquisition of C.R. Bard‘s (NYSE:BCR) electrophysiology business, in November. The deal is expected to help accelerate launches of key EP technologies including its IntellaTip MiFi XP ablation catheter and Rhythmia mapping system.
